Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
This study is evaluating the drugs nab-paclitaxel and gemcitabine in combination with avutometinib (VS-6766) and defactinib for patients with pancreatic ductal adenocarcinoma.
Nab-paclitaxel and gemcitabine are anti-cancer chemotherapy drugs used to kill cancer cells by stopping cell division and causing cell death. Nab-paclitaxel in combination with gemcitabine is approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment for patients with pancreatic ductal adenocarcinoma. Both nab-paclitaxel and gemcitabine are given intravenously (through a vein in the arm) or through a port (small device implanted beneath the skin to make intravenous treatments easier). A central line, which is a bigger catheter that’s put into a large vein in the chest or arm, may also be placed depending on a participant’s circumstances.
VS-6766 (avutometinib) and defactinib are a type of drug called kinase inhibitors. Kinase inhibitors block cancer growth by disrupting signals that tell the cancer cells to divide. Both are given in pill form and are taken by mouth.
The combination of these 4 study drugs is considered investigational, which means the combination has not yet been approved by the FDA.
This study is trying to find out what the best dose of each study drug in combination will be. Another goal of the study is to see if the combination will provide a treatment benefit to participants with your diagnosis.
There are 3 possible dose combinations. The study team will discuss the assigned doses with each participant.
Total study participation depends on how well each participant responds to the treatments.
Inclusion Criteria:
1. Males or females over the age of 18 years of age
2. Confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma.
3. Agreement to use highly effective method of contraceptive
Exclusion Criteria:
1. Patients with pancreatic neuroendocrine tumors
2. Prior or concomitant treatment for metastatic pancreatic ductal adenocarcinoma
Detailed eligibility will be discussed when contacting the study team.